Can Tan, a research assistant professor at Northwestern Medicine in Chicago, leaned over a microscope in 2026, studying the delicate heart valves of mice with Marfan syndrome—and saw something no one had noticed before: the tiny lymphatic vessels meant to drain fluid and calm inflammation were barely there. That moment sparked a discovery that’s reshaping how scientists understand one of the most dangerous complications of Marfan syndrome, a genetic disorder affecting 1 in 5,000 people worldwide. For decades, researchers knew that mutations in the FBN1 gene weakened connective tissue and often led to myxomatous degeneration of the mitral valve (MDMV), a condition that can cause mitral valve prolapse, severe blood leakage, and even sudden cardiac death. But the precise biological pathway from gene flaw to heart failure remained a mystery—until now. Tan and senior author Tsutomu Kume, Ph.D., revealed that dysfunctional lymphatic vessels in the mitral valve are not just bystanders but active drivers of the disease. In healthy mice, lymphatic vessels develop in the mitral valve shortly after birth, helping maintain structural integrity. But in Marfan syndrome mice, these vessels were fewer, underdeveloped, and structurally impaired, leading to fluid buildup, chronic inflammation, and rapid valve degeneration. “If the lymphatic vessels are dysfunctional and cannot drain interstitial fluid, the valve’s connective tissue becomes softer and thicker, a condition known as myxomatous degeneration,” Kume explained. This insight builds on the team’s earlier 2023 discovery—that lymphatic vessels even exist in the adult mouse mitral valve—a finding so unexpected it overturned long-held assumptions in cardiac biology. The implications are profound. Currently, many Marfan patients with severe mitral valve disease face open-heart surgery, a high-risk procedure often requiring lifelong recovery and follow-up. But the Northwestern team tested two promising interventions in mice: delivering vascular endothelial growth factor C (VEGFC) to stimulate lymphatic regrowth, and using the FDA-approved drug fingolimod to reduce inflammation and restore lymphatic function. Both treatments improved lymphatic vessel density, reduced immune cell buildup, and slowed valve degeneration. “Our research shifts the paradigm in the field by revealing a previously overlooked driver of heart valve failure: lymphatic dysfunction,” Tan said. The ultimate goal? To develop non-surgical therapies that prevent heart failure before it starts. While human trials are still ahead, this work opens a new frontier in treating not just Marfan syndrome, but potentially other forms of mitral valve disease as well. For a condition once thought to be managed only by the scalpel, the future may now lie in a syringe.